Blogger edition published 10 October 2026 · Source updated 10 October 2026. Original publication dates are preserved; the website import date is not used.
Historical article. Figures, holdings and views reflect the original publication, not current conditions. Claims are preserved, not independently revalidated. Capital at risk.
We executed a strategic reallocation representing approximately 10% of our total portfolio assets entering Q4. This capital was redeployed to manage valuation risk and expand our chokepoint thesis into foundational operating platforms.
The Exits: Managing Multiples and Concentration
Datadog (DDOG): We liquidated this position entirely. While the underlying business fundamentals remain strong, the prevailing price-to-earnings multiple (>500x) presents asymmetric downside risk. In a shifting yield environment, mathematical certainty in valuation is required. The current premium cannot be justified exclusively by projected free cash flow expansion.
SanDisk (SNDK): This execution was a tactical reduction in aggregate memory sector concentration. We maintain our primary high-bandwidth memory exposure through Micron (MU), but scaling back our total sector weight protects the portfolio against cyclical inventory risks.
The Initiations: Enterprise Ontology and Biological Compute
Palantir (PLTR): We initiated a position to secure the structural monopoly in enterprise AI deployment. Hardware compute is ineffective without structured data ontologies. Palantir operates as the definitive operating system for institutional and governmental data integration, possessing an unbreachable moat in high-security environments.
Moderna (MRNA): This expands our thesis beyond digital hardware into biological compute. We classify Moderna as an information technology platform applied to biology, rather than a traditional pharmaceutical equity. Their mRNA architecture functions as a programmable foundation for next-generation therapeutics, offering exposure to a revolutionary technological chokepoint.
Our cash position remains near zero. We remain fully deployed in the physical monopolies and operating systems driving the global economy.
Copier Blueprint
My live reallocations are executed automatically for all copiers on eToro. To mirror this updated portfolio:
Search for razvancd.
Click Copy and check "Copy Open Trades" to instantly acquire PLTR, MRNA, and our core monopolies.
Minimum recommended allocation: $500.Copy Trading is not investment advice | Capital at risk | Past performance does not guarantee future results.
eToro version · 7 October 2026
This published adaptation is preserved in full alongside the Blogger article.
𝗣𝗼𝗿𝘁𝗳𝗼𝗹𝗶𝗼 𝗔𝗹𝗹𝗼𝗰𝗮𝘁𝗶𝗼𝗻 𝗨𝗽𝗱𝗮𝘁𝗲: 𝗘𝘅𝗶𝘁𝗶𝗻𝗴 𝗗𝗗𝗢𝗚 & 𝗦𝗡𝗗𝗞, 𝗜𝗻𝗶𝘁𝗶𝗮𝘁𝗶𝗻𝗴 𝗣𝗟𝗧𝗥 & 𝗠𝗥𝗡𝗔
We have executed a strategic reallocation representing approximately 10% of our portfolio assets. This capital has been redeployed to manage valuation risk and expand our exposure to foundational platform technologies.
𝗧𝗵𝗲 𝗘𝘅𝗶𝘁𝘀: 𝗠𝗮𝗻𝗮𝗴𝗶𝗻𝗴 𝗠𝘂𝗹𝘁𝗶𝗽𝗹𝗲𝘀 𝗮𝗻𝗱 𝗖𝗼𝗻𝗰𝗲𝗻𝘁𝗿𝗮𝘁𝗶𝗼𝗻
• Sold $DDOG (Datadog): While the underlying business remains strong, the current price-to-earnings (>500x) multiple presents asymmetric downside risk. In a shifting yield environment, we require mathematical certainty in valuation, and the current premium cannot be justified by projected free cash flow expansion alone.
• Sold $SNDK (SanDisk): This was a tactical reduction in memory sector concentration. We maintain our primary memory exposure through $MU, but scaling back aggregate sector weight protects the portfolio from cyclical inventory risks.
𝗧𝗵𝗲 𝗜𝗻𝗶𝘁𝗶𝗮𝘁𝗶𝗼𝗻𝘀: 𝗘𝗻𝘁𝗲𝗿𝗽𝗿𝗶𝘀𝗲 𝗢𝗻𝘁𝗼𝗹𝗼𝗴𝘆 𝗮𝗻𝗱 𝗕𝗶𝗼𝗹𝗼𝗴𝗶𝗰𝗮𝗹 𝗖𝗼𝗺𝗽𝘂𝘁𝗲
• Bought $PLTR (Palantir): We are securing the chokepoint of enterprise AI deployment. Hardware compute is useless without structured data ontologies. Palantir operates as the definitive operating system for institutional and governmental data integration, possessing a structural monopoly in high-security environments.
• Bought $MRNA (Moderna): This expands our thesis beyond digital hardware into biological compute. Moderna is not a traditional pharmaceutical company; it is an information technology platform applied to biology. Their mRNA technology functions as a programmable foundation for next-generation therapeutics. We allocate capital here to capture the extreme growth potential of a revolutionary platform technology.
Our cash position remains near zero. We remain fully deployed in the structural monopolies driving the global economy.
Copy Trading is not investment advice | Capital at risk | Past performance does not guarantee future results. Full disclosures.
